IP Library Granted Patent US 7,534,455
Granted Patent B2
US 7,534,455 · App. 11/100,433 · Granted May 19, 2009

Herbal composition PHY906 and its use in chemotherapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,534,455
App. No.
11/100,433
Granted
May 19, 2009
Kind
B2
Abstract

This invention provides herbal compositions useful for increasing the therapeutic index of drugs, including those used in the treatment of disease, especially viral infections and neoplasms of cancer. This invention provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a person undergoing such chemotherapy.

Claims (7)

1. A composition comprising:

i) a pharmaceutically acceptable carrier;

ii) an herbal preparation consisting essentially of Scutellaria, Glycyrrhiza, Ziziphus and Paeonia ; and

iii) a chemotherapeutic formulation comprising one or more chemotherapeutic compounds selected from the group consisting of doxorubicin, thalidomide, capecitabine, gemcitabine, and oxaliplatin.

2. A composition of claim 1 , wherein the chemotherapeutic formulation further comprises 5-fluorouracil (5FU) and leucovorin (LV).

3. The composition of claim 1 , wherein the herbal preparation consists of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba, and Paeonia lactiflora.

4. A method of relieving side effects of a chemotherapeutic compound in a mammal comprising administering a composition comprising: i) a pharmaceutically acceptable carrier; ii) an herbal preparation consisting essentially of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba and Paeonia lactiflora ; and iii) a chemotherapeutic formulation comprising the chemotherapeutic compound selected from the group consisting of doxorubicin, thalidomide, capecitabine, gemcitabine, and oxaliplatin.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2021
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057973/0751 →
TERMINATION OF PATENT AND TRADEMARK SECURITY AGREEMENT Recorded Nov 25, 2019
From: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
To: KADMON CORPORATION, LLC
Reel/Frame 051106/0677 →
SECURITY INTEREST Recorded Sep 8, 2015
From: KADMON CORPORATION, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036573/0001 →
RELEASE OF SECURITY INTEREST Recorded Sep 1, 2015
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 036518/0862 →
SECURITY INTEREST Recorded Aug 31, 2015
From: KADMON CORPORATION, LLC
To: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
Reel/Frame 036515/0084 →
SECURITY AGREEMENT Recorded Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0116 →
SECURITY AGREEMENT Recorded Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0212 →